The Role of Sex in Predicting Immunotherapy Response in Advanced Cutaneous Squamous Cell Carcinoma

Nicolas Yeo^*
*Correspondence: Nicolas Yeo, Department of Medicine, University of Wollongong, Wollongong, Australia, Email:

Keywords

Squamous cell • Dimorphism • Sex

Introduction

To comprehend the role of sex in immunotherapy response, it is essential to grasp the underlying biological differences in the immune system between males and females. These differences have been well-documented and can significantly affect immune responses to various diseases, including cancer. One key factor contributing to sex-related differences in the immune system is the role of sex hormones. Estrogen, progesterone, and testosterone have varying effects on immune cells. For instance, estrogen can enhance the immune response, promoting the proliferation of certain immune cells, such as T cells. In contrast, testosterone may suppress immune function. These hormonal differences can result in variations in immune responses to diseases and treatments, including immunotherapy. This heightened immune activation may contribute to improved immunotherapy outcomes in some female patients with cSCC. However, it is essential to note that the relationship between immune activation and cancer response can be complex, as an overly aggressive immune response can lead to autoimmune reactions and adverse events [1].

Immunotherapy has revolutionized the treatment landscape for several types of cancer, including advanced cSCC. The most widely used class of immunotherapies for cancer treatment is immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies. These drugs work by blocking the interaction between these proteins, which often prevent immune cells from recognizing and attacking cancer cells. By inhibiting these checkpoints, immunotherapy enhances the immune system's ability to target and eliminate cancerous cells. Immunotherapy has demonstrated remarkable success in a subset of patients with advanced cSCC. However, not all patients respond equally to these treatments. Predictive biomarkers are essential for identifying individuals who are likely to benefit from immunotherapy, and understanding the role of sex in this context is becoming increasingly important. Research into sex-related differences in immunotherapy response has provided valuable insights into the potential impact of sex on treatment outcomes in advanced cSCC [2].

Literature Review

Several studies have reported differences in response rates to immunotherapy based on sex. In some cancers, including melanoma and lung cancer, female patients have exhibited higher response rates to immune checkpoint inhibitors compared to their male counterparts. While the data specific to cSCC is limited, these findings suggest that sex-related differences in immunotherapy response may extend to this type of cancer as well. Improved response rates in female patients have often translated into better survival outcomes. In some cancer types, females treated with immunotherapy have shown prolonged progression-free survival and overall survival compared to males. These findings suggest that sex may be a valuable prognostic factor in predicting patient outcomes in the context of immunotherapy for advanced cSCC.

The observed sex-related differences in immunotherapy response may be attributed to various underlying mechanisms, including the biological factors discussed earlier. These mechanisms can interact in complex ways to influence the effectiveness of immunotherapy in male and female patients. Sex hormones can directly affect the immune response to immunotherapy. Estrogen, for example, has been shown to enhance the activity of immune cells, making female patients more responsive to immunotherapy. Conversely, the immunosuppressive effects of testosterone may reduce the efficacy of immunotherapy in male patients. These hormonal differences may contribute to the variations in treatment outcomes observed between sexes. The differences in immune cell composition and function between males and females can also play a role in immunotherapy response [3].

Discussion

The heightened immune activation typically observed in females may contribute to their improved response to immunotherapy. This stronger immune activation can lead to more effective cancer cell recognition and elimination. However, it is crucial to strike a delicate balance, as excessive immune activation can also result in autoimmune reactions and severe side effects. Therefore, the optimal level of immune activation for immunotherapy success may vary between male and female patients. The recognition of sex-related differences in immunotherapy response has important clinical implications for the management of advanced cSCC. Understanding these differences can aid in treatment decision-making and potentially improve outcomes for patients. The identification of sex as a potential predictive factor for immunotherapy response suggests that treatment decisions should be personalized based on a patient's sex. While sex is not the sole determinant of response, it can be a valuable consideration in the overall clinical assessment. Physicians can use this information to discuss treatment options with their patients and make more informed decisions.

The discovery of sex-related differences in immunotherapy response highlights the need for further research into biomarkers that can more accurately predict which patients will benefit from these treatments. While sex is a helpful indicator, it is not a comprehensive biomarker on its own. Identifying specific markers that can better predict treatment response will be critical for improving patient care. The sex-related differences in immunotherapy response emphasize the importance of including a diverse patient population in clinical trials. Historically, clinical trials in oncology have been predominantly male-centric, limiting the generalizability of their results to female patients. By ensuring greater representation of both sexes in clinical trials, researchers can generate more comprehensive data on treatment outcomes and better understand the role of sex in immunotherapy response [4-6].

Conclusion

While the impact of sex on immunotherapy response in advanced cSCC is a promising area of research, several challenges and areas for future investigation remain.The biological underpinnings of sex differences in immunotherapy response are complex and multifaceted. Research in this field requires a deeper understanding of how sex hormones, immune cell composition, and immune activation interplay to influence treatment outcomes. Further studies are needed to unravel the precise mechanisms at work. It is crucial to recognize that sex is just one facet of patient heterogeneity. Various other factors, including genetics, age, and overall health status, can also impact immunotherapy response. Research should focus on developing comprehensive predictive models that consider multiple variables to make more accurate treatment decisions.

Acknowledgement

None.

Conflict of Interest

There is no conflict of interest by author.

References

1. Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel and Mathieu Laversanne, et al. "Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries." CA Cancer J Clin 71 (2021): 209-249.

Google Scholar, Crossref, Indexed at

2. Soura, Efthymia, Eleni Gagari and Alexander Stratigos. "Advanced cutaneous squamous cell carcinoma: How is it defined and what new therapeutic approaches are available?." Curr Opin Oncol 31 (2019): 461-468.

Google Scholar, Crossref, Indexed at

3. Ashford, Bruce G., Jonathan Clark, Ruta Gupta and N. Gopalakrishna Iyer, et al. "Reviewing the genetic alterations in high‐risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets." Head Neck 39 (2017): 1462-1469.

Google Scholar, Crossref, Indexed at

4. Guminski, Alexander and Brian Stein. "Immunotherapy and other systemic therapies for cutaneous SCC." Oral Oncol 99 (2019): 104459.

Google Scholar, Crossref, Indexed at

5. Munhoz, Rodrigo R., Guilherme Nader‐Marta, Veridiana P. de Camargo and Marcello M. Queiroz, et al. "A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma." Cancer 128 (2022): 4223-4231.

Google Scholar, Crossref, Indexed at

6. Bumanlag, Isabela M., Joseph Abi Jaoude, Michael K. Rooney and Cullen M. Taniguchi, et al. "Exclusion of older adults from cancer clinical trials: Review of the literature and future recommendations." In Seminars in radiation oncology 32 (2022): 125-134.

Google Scholar, Crossref, Indexed at